Hera named one of 'Top 10 Healthcare Startups' at SOUTH SUMMIT MADRID 2019
Hera Health Solutions is named one of Top 10 Companies to participate in the South Summit Fund Startup Competition 2019
(July 29, 2018) – Hera Health Solutions Inc. announced today that they were named one of the Top Ten Finalist Startups to compete in the South Summit Fund Startup Competition 2019. From a pool of more than more than 3,700 startups coming from 115 countries, the list was reduced to the final 100 most promising startups around the globe.
South Summit is the Leading Innovation Global Platform focused on business opportunities and disruptive trends, that gathers together the entrepreneurial ecosystem. This year, the South Summit competition had huge presence from overseas, amounting to a total of 62% international projects. The most represented include Colombia, Israel, India, UK, Germany, France, Colombia, Mexico, and USA.
During previous editions, companies like Amadix went through the competition. Other featured winning startups include, Wallbox, winner in 2017, who is predicted to reach in 2019 17M€ in revenue, as well as Spotahome, winner in 2016, that has already raised 65M$ in investment and has presence in 65 countries.
95% of the startups finalists in previous editions are presently active and have recorded more than 2.6Bn$ in investment. Don't miss out on the chance to meet these outstanding disruptors! South Summit is one of the leading innovation platforms in Europe which connects the most disruptive startups with worldwide investors and corporations seeking to improve their global competitiveness through innovation. South Summit will be held on 2-4 October 2019 in Madrid (Spain) and South Summit Colombia Pacific Alliance will be held on June 20th 2019 in Bogotá (Colombia).
ABOUT HERA HEALTH SOLUTIONS INC.
Hera Health Solutions (HHS) is a pharmaceutical device company seeking to redefine the way people take long-term prescription drugs. HHS specializes in the research, development and commercialization of long term treatments through proprietary biodegradable implants by using existing generic drugs in combination with already FDA-approved structural materials.